Ipamorelin
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
Ipamorelin is a synthetic pentapeptide — a chain of five amino acids — classified as a growth-hormone secretagogue. Rather than supplying growth hormone directly, it signals the body’s own pituitary gland to release a pulse of growth hormone. It was first described in the late 1990s and is often grouped with peptides like sermorelin and CJC-1295 in growth-hormone-focused discussions.
Ipamorelin is best known for its selectivity: in early research it raised growth-hormone levels while having little effect on other hormones such as cortisol and prolactin. Human data remains limited, and ipamorelin is not approved by any major regulator for therapeutic use.
How it works
Ipamorelin is an agonist of the ghrelin receptor, also called the growth-hormone secretagogue receptor. By binding this receptor on the pituitary gland, it triggers the release of stored growth hormone in a pulse that mimics the body’s natural rhythm.
A defining feature reported in the foundational research is its selectivity. Compared with earlier growth-hormone-releasing peptides, ipamorelin stimulated growth-hormone release without meaningfully raising cortisol, prolactin, or ACTH. The precise long-term effects in humans are not established.
Reported benefits
- Stimulation of the body’s own growth-hormone release (a selective, pulse-like response)
- Interest in recovery, body composition, and general wellness contexts
- A cleaner hormonal profile than older secretagogues in preclinical comparisons
These are reported effects, not guaranteed outcomes.
Considerations & side effects
Because rigorous long-term human trials are lacking, the full safety profile of ipamorelin is not well characterized. Reported side effects are generally mild and include injection-site irritation, headache, flushing, lightheadedness, and transient water retention.
As a compound that acts on the growth-hormone axis, it is not appropriate for casual use, and product purity varies widely in the research-chemical market. It is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is ipamorelin?
A synthetic pentapeptide (five amino acids) that acts as a selective growth-hormone secretagogue, prompting the pituitary gland to release its own growth hormone. It was originally developed by Novo Nordisk in the late 1990s.
Is ipamorelin FDA-approved?
No. Ipamorelin is not approved by the FDA or any major regulator for human therapeutic use, and is sold for research purposes only.
How is ipamorelin different from other growth-hormone-releasing peptides?
It is one of the most selective compounds in its class. In studies it stimulated growth-hormone release with little effect on cortisol, prolactin, or other secondary hormone pathways, unlike earlier secretagogues such as GHRP-6.
How is ipamorelin typically administered?
Most commonly by subcutaneous injection after reconstitution with bacteriostatic water.
References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. ↗
- Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. ↗
- Venkova K, et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. ↗
Related compounds
Pre-mixed blend of CJC-1295 (no DAC) and Ipamorelin for synergistic growth hormone release. Classic GH secretagogue combination sold as a single vial.
Modified GRF (1-29). Growth hormone releasing hormone analog. Often combined with Ipamorelin for synergistic GH release.
CJC-1295 with Drug Affinity Complex. Extended half-life version providing sustained GH elevation. Once or twice weekly dosing.